Céline Guien

Céline Guien

Auto-generated profile, based on publicly available information

Céline Guien

Aix Marseille Univ, INSERM, MMG, Bioinformatics & Genetics, Marseille, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
CCCharles E. Chapple
Charles E. Chapple
BRBenoit Robisson
Benoit Robisson
LSLionel Spinelli
Lionel Spinelli
CGCéline Guien
Céline Guien
EBEmmanuelle Becker
Emmanuelle Becker
CBChristine Brun
Christine Brun
Moonlighting proteins are a subclass of multifunctional proteins whose functions are unrelated. Although they may play important roles in cells, there has been no large-scale method to identify them, nor any effort to characterize them as a group. Here, we propose the first method for the identification of ‘extreme multifunctional’ proteins from an interactome as a first step to characterize moonlighting proteins. By combining network topological information with protein annotations, we identify 430 extreme multifunctional proteins (3% of the human interactome). We show that the candidates form a distinct sub-group of proteins, characterized by specific features, which form a signature of extreme multifunctionality. Overall, extreme multifunctional proteins are enriched in linear motifs and less intrinsically disordered than network hubs. We also provide MoonDB, a database containing information on all the candidates identified in the analysis and a set of manually curated human moonlighting proteins.

18 October 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
PRPauline Romanet
Pauline Romanet
AMAmira Mohamed
Amira Mohamed
SGSophie Giraud
Sophie Giraud
MOMarie-Françoise Odou
Marie-Françoise Odou
MNMarie-Odile North
Marie-Odile North
ABAnne Barlier
Anne Barlier
Context Multiple Endocrine Neoplasia type 1 (MEN1) is an autosomal dominant disease caused by mutations in the MEN1 gene characterized by a broad spectrum of clinical manifestations, of which the most frequent are primary hyperparathyroidism, pituitary adenomas, and neuroendocrine tumors. Objective The aim of this work is to facilitate interpretation of variants and improve the genetic counseling and medical care of MEN1-patients’ families. Design, Setting, and Patients The TENGEN network (French oncogenetics network of neuroendocrine tumors) has interpreted and collected all allelic variants and clinical characteristics of the MEN1-positive patients identified through genetic testing performed in the French population from 1997 to 2015. They were registered in a locus-specific database called the UMD-MEN1 database (www.umd.be/MEN1/). Main Outcomes variant classification, age-related penetrance, odds ratio. Results Three hundred seventy distinct variants reported in 1,676 patients, including 181 unpublished variants, have currently been registered. This database analysis pointed out the low frequency of benign or likely benign missense variants in MEN1 (only 6.6%). Eight families (1.9%) presented a familial isolated hyperparathyroidism and harbored the same mutation found in authentic MEN1-families. An association exists between large rearrangements and an earlier onset of the disease, whereas no difference was observed between truncating and non-truncating variants. Conclusion UMD-MEN1 database provides an exhaustive overview of the MEN1 variants present in the French population. For each variant, a classification is publicly available. Clinical data collections allow the determination of genotype-phenotype correlation and age-related penetrance of lesions in the cohort.

1 March 2020 in JACC
Verified
Journal Article
Closed access
OMOlivier Milleron
Olivier Milleron
FAFlorence Arnoult
Florence Arnoult
GDGabriel Delorme
Gabriel Delorme
DDDelphine Detaint
Delphine Detaint
QPQuentin Pellenc
Quentin Pellenc
GJGuillaume Jondeau
Guillaume Jondeau

4 December 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CGCéline Guien
Céline Guien
GBGaëlle Blandin
Gaëlle Blandin
PLPauline Lahaut
Pauline Lahaut
BSBenoît Sanson
Benoît Sanson
KNKatia Nehal
Katia Nehal
CBChristophe Béroud
Christophe Béroud
Facioscapulohumeral muscular dystrophy is a rare inherited neuromuscular disease with an estimated prevalence of 1/20,000 and France therefore harbors about 3000 FSHD patients. With research progress and the development of targeted therapies, patients’ identification through registries can facilitate and improve recruitment in clinical trials and studies. The French National Registry of FSHD patients was designed as a mixed model registry involving both patients and physicians, through self-report and clinical evaluation questionnaires respectively, to collect molecular and clinical data. Because of the limited number of patients, data quality is a major goal of the registry and various automatic data control features have been implemented in the bioinformatics system. In parallel, data are manually validated by molecular and clinical curators. Since its creation in 2013, data from 638 FSHD patients have been collected, representing about 21% of the French FSHD population. The mixed model strategy allowed to collect 59.1% of data from both patients and clinicians; 26 and 14.9% from respectively patients and clinicians only. With the identification of the FSHD1 and FSHD2 forms, specific questionnaires have been designed. Though FSHD2 patients are progressively included, FSHD1 patients still account for the majority (94.9%). The registry is compatible with the FAIR principles as data are Findable, Accessible and Interoperable. We thus used molecular standards and standardized clinical terms used by the FILNEMUS French network of reference centers for the diagnosis and follow-up of patients suffering from a rare neuromuscular disease. The implemented clinical terms mostly map to dictionaries and terminology systems such as SNOMED-CT (75% of terms), CTV3 (61.7%) and NCIt (53.3%). Because of the sensitive nature of data, they are not directly reusable and can only be accessed as aggregated data after evaluation and approval by the registry oversight committee. The French National Registry of FSHD patients belongs to a national effort to develop databases, which should now interact with other initiatives to build a European and/or an international FSHD virtual registry for the benefits of patients. It is accessible at www.fshd.fr and various useful information, links, and documents, including a video, are available for patients and professionals.

1 March 2019 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
OMOlivier Milleron
Olivier Milleron
JRJacques Ropers
Jacques Ropers
FAFlorence Arnoult
Florence Arnoult
CBClaire Bouleti
Claire Bouleti
GDGabriel Delorme
Gabriel Delorme
GJGuillaume Jondeau
Guillaume Jondeau
Background: Both bicuspid aortic valve (BAV) and Marfan syndrome have been associated with aortic dissection risk, but it is unknown whether the presence of BAV is associated with an increased aortic risk in patients with an FBN1 gene mutation. We evaluated aortic diameters, aortic valve function, and aortic shape in Marfan syndrome patients with and without BAV and reported aortic events during follow-up. Methods: All patients with an FBN1 gene mutation evaluated in our clinic were included. Aortic root diameters were measured, and the aortic valve was studied using echocardiography at each visit. Results: Of the 1437 patients with an FBN1 gene mutation, 26 patients (1.8%) had a BAV. Both aortic root maximal diameter and normalized Z score were larger at all ages, in patients with BAV when compared with patients with tricuspid aortic valve. Prophylactic aortic root surgery tended to be performed in younger patients when BAV was present, although aortic diameter threshold was similar in the 2 populations. No aortic dissection was observed in Marfan syndrome patients with BAV. Conclusions: In patients with a FBN1 mutation, BAV is associated with larger aortic root diameter, with no difference in evolution of Z score with age. We found a trend towards prophylactic aortic root surgery at younger ages but similar aortic diameter thresholds without occurrence of aortic dissection. We did not find any evidence for lowering aortic diameter thresholds used to propose preventive aortic root surgery in the presence of BAV in patients with FBN1 mutations.

1 December 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
FKFlorence Koeppel
Florence Koeppel
EMEtienne Muller
Etienne Muller
AHAlexandre Harlé
Alexandre Harlé
CGCéline Guien
Céline Guien
PSPierre Sujobert
Pierre Sujobert
ISIsabelle Soubeyran
Isabelle Soubeyran